FOUNDATIONONE®CDx

PATIENT
Sample, Jane

TUMOR TYPE
Breast carcinoma (NOS)

REPORT DATE
01 Jan 2018

QRF#
XXXXXXXX

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT

DISEASE Breast carcinoma (NOS)
NAME Not Given
DATE OF BIRTH Not Given
SEX Not Given
MEDICAL RECORD # Not Given

PHYSICIAN

ORDERING PHYSICIAN Not Given
MEDICAL FACILITY Not Given
ADDITIONAL RECIPIENT Not Given
MEDICAL FACILITY ID Not Given
PATHOLOGIST Not Given

SPECIMEN

SPECIMEN SITE Not Given
SPECIMEN ID Not Given
SPECIMEN TYPE Not Given
DATE OF COLLECTION Not Given
SPECIMEN RECEIVED Not Given

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - TMB-Low (3 Muts/Mb)

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

ERBB2 amplification
PIK3CA H1047R
CDK12 rearrangement exon 5
CCNE1 amplification
NOTCH3 AKAP8-NOTCH3 fusion
TP53 T253fs*11

2 Disease-relevant genes with no reportable alterations: ***BRCA1, BRCA2***

10 Therapies with Clinical Benefit
0 Therapies with Lack of Response
24 Clinical Trials

BIOMARKER FINDINGS	ACTIONABILITY
Microsatellite status - MS-Stable	No therapies or clinical trials. see Biomarker Findings section
Tumor Mutational Burden - TMB-Low (3 Muts/Mb)	No therapies or clinical trials. see Biomarker Findings section

GENOMIC FINDINGS	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
ERBB2 **-** amplification	[redacted]	[redacted]
10 Trials see p. 16		
PIK3CA **-** H1047R	[redacted]	[redacted]
7 Trials see p. 18		
CDK12 **-** rearrangement exon 5	None	None
9 Trials see p. 20		

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.